Allergan confirms generic Rytary patent challenge

Allergan's ANDA product is a generic version of Impax Laboratories' Rytary.

Allergan has filed an Abbreviated New Drug Application (ANDA) with FDA seeking approval to market Carbidopa and Levodopa Extended-release Capsules, 61.25 mg/245 mg, 23.75 mg/95 mg, 36.25 mg/145 mg and 48.75 mg/195 mg. Allergan's ANDA product is a generic version of Impax Laboratories' Rytary, which is indicated for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

Impax Laboratories, filed suit against Allergan on 17 August 2015 in the US District Court for the District of New Jersey seeking to prevent Allergan from commercializing its ANDA product prior to the expiration of certain US Patents. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Allergan's ANDA for up to 30 months from the date the plaintiffs received notice of Allergan's ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.

Based on available information, Allergan believes it may be a "first applicant" to file an ANDA for the generic version of Rytary and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity.

For the 12 months ending 31 July 2015, Rytary had total US sales of approximately $15 million, according to IMS Health data.

Related News

News Pharmaceutical industry supports COP28 health stance in joint statement

As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb...

6 Dec 2023
News Biden backs Cold-War measures to shore-up medical supply chains

In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies.

29 Nov 2023
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?

In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field.

25 Oct 2023
News Which 10 drugs are open to price negotiation with Medicare in the USA?

The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA).

5 Sep 2023
News 10 Major Drug Approvals So Far in 2023

Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre...

28 Jun 2023
News Novartis agrees for copies to be made of cancer drug to reach poorer countries

Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries.

26 Jun 2023
News CPHI Podcast Series: outsourcing and manufacturing trends

Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.

14 Jun 2023
News New WHO health emergency guidelines expect full transparency from Big Pharma

The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.

22 Nov 2022